![Pawel Kalinski: The use of TAAs as ubiquitous targets for adoptive T cell therapies in solid tumors](https://oncodaily.com/pub/uploads/2024/09/Pawel-Kalinski-e1725375553227.jpg)
Photo taken from Pawel Kalinski/LinkedIn
Sep 3, 2024, 12:16
Pawel Kalinski: The use of TAAs as ubiquitous targets for adoptive T cell therapies in solid tumors
Pawel Kalinski, Senior Vice President for Team Science at Roswell Park Comprehensive Cancer Center, shared on LinkedIn:
“Contratulatuons to Dr. Dong for his impressive PhD thesis and for this critical contribution to our understanding of how cytotoxic lymphocytes (CTLs) can selectively recognize low levels of unmutated tumor-associated antigens (TAAs) on cancer cells, but not the same antigens expressed by healthy tissues
Best wishes for his postdoctoral research at our lab in developing a new class of T cell therapies, using dual recognition by TCR (or CAR) and NK receptors (NKRs) to allow the use of TAAs as ubiquitous targets for adoptive T cell therapies (ACT) in solid tumors.
Authors:
”Source: Pawel Kalinski/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2024, 10:55